Identifying <font color="red">patients_1</font> <font color="red">at_1</font> <font color="red">high_1</font> <font color="red">risk_1</font> <font color="red">for_1</font> <font color="red">neutropenic_1</font> <font color="red">complications_1</font> <font color="red">during_1</font> <font color="red">chemotherapy_2</font> <font color="red">for_2</font> <font color="red">metastatic_2</font> <font color="red">breast_2</font> <font color="red">cancer_2</font> <font color="red">with_1</font> <font color="red">doxorubicin_1</font> <font color="red">or_1</font> <font color="red">pegylated_1</font> <font color="red">liposomal_1</font> <font color="red">doxorubicin_1</font> <font color="red">:_1</font> the development of a prediction model . 
<br>
<br> OBJECTIVE To develop a cycle - based risk prediction model for <font color="red">neutropenic_1</font> <font color="red">complications_1</font> <font color="red">(_1</font> <font color="red">NC_1</font> <font color="red">)_1</font> <font color="red">during_1</font> <font color="red">chemotherapy_2</font> <font color="red">with_1</font> <font color="red">doxorubicin_1</font> <font color="red">(_1</font> <font color="red">DOX_1</font> <font color="red">)_1</font> <font color="red">or_1</font> <font color="red">a_1</font> <font color="red">pegylated_1</font> <font color="red">liposomal_1</font> <font color="red">formulation_1</font> <font color="red">(_1</font> <font color="red">PLD_1</font> <font color="red">)_1</font> <font color="red">for_1</font> <font color="red">patients_2</font> <font color="red">with_2</font> <font color="red">metastatic_2</font> <font color="red">breast_2</font> <font color="red">cancer_2</font> <font color="red">(_2</font> <font color="red">MBC_2</font> <font color="red">)_2</font> <font color="red">._2</font> 
<br> METHODS Data analyzed was from a phase III , randomized clinical trial of DOX ( 60 mg / m(2 ) every 3 weeks ) or PLD ( 50 mg / m(2 ) every 4 weeks ) for the first line therapy for <font color="red">MBC_1</font> ( <font color="red">n_1</font> <font color="red">=_1</font> <font color="red">509_1</font> <font color="red">)_1</font> ( O'Brien et al , Ann Oncol . 2004;15:440 - 449 ) . NC were defined as an absolute neutrophil count < or = 1.5 x 10(9 ) cells / L ( ie , > or = grade II ) before the next cycle , febrile neutropenia or neutropenia with a documented infection . Patient and hematologic factors potentially associated with NC were evaluated . Factors with a P value of < or = 0.25 within a cycle were included in a generalized estimating equations regression model . Using backward elimination , we derived a risk scoring algorithm ( range 0 - 63 ) from the final reduced model . 
<br> RESULTS Risk factors retained in the model included poor performance status , absolute neutrophil count < or = 2.0 x 10(9 ) cells / L in the previous cycle , the first cycle of chemotherapy , DOX versus PLD and advanced age . A precycle risk score from > or = 25 to < 40 for a given patient was identified as being the optimal threshold for sensitivity ( 58.0% ) and specificity ( 78.7% ) . Patients with a score at or beyond this threshold would be considered at high risk for developing NC in later cycles . 
<br> CONCLUSION The use of this model may enhance patient care by targeting preventative therapies ( eg , granulocyte colony stimulating factor or PLD ) to those <font color="red">MBC_2</font> <font color="red">patients_2</font> <font color="red">most_1</font> <font color="red">likely_1</font> <font color="red">to_1</font> <font color="red">experience_1</font> <font color="red">NC_1</font> <font color="red">during_1</font> <font color="red">anthracycline_2</font> <font color="red">-_2</font> <font color="red">based_2</font> <font color="red">chemotherapy_2</font> <font color="red">._2</font>